by admin | Nov 3, 2021 | Press Release
Seattle, WA, November 3, 2021 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced a research collaboration with a top-three animal health company to develop orally delivered biologic...
by admin | Oct 29, 2021 | News
Abstract Circular tandem repeat proteins (‘cTRPs’) are de novo designed protein scaffolds (in this and prior studies, based on antiparallel two-helix bundles) that contain repeated protein sequences and structural motifs and form closed circular structures. They can...
by admin | Oct 12, 2021 | News
Our industry’s response to COVID-19 defied the conventional wisdom that it takes years to deliver new drugs. Makers of monoclonal antibodies led the pack, most notably Regeneron (NSDQ:REGN), which manufactured the 8-g, two-antibody cocktail administered to...
by admin | Oct 6, 2021 | News
By Brian Finrow and Jim Roberts Today, Lumen announced significant new federal funding covering a Phase 2 clinical trial of our Covid-19 product, LMN-301. It is, we believe, the world’s first clinical program directed specifically at the GI manifestations of Covid-19....
Cognition Live Article on RePreve Trial
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis
Q&A: Biologic drugs are reinvented to treat infectious diseases